I think a lot of folks had not expected them to be back this quickly.
The deal will proceed if J&J will get the price it wants. I am not sure Guidant will give them that price.
While it could be a knock-out blow, at what point are we overpaying? I think we could be getting close to that point based on the cardiac rhythm business.
When you have a look at the potential liability they have in infringement cases, you basically could save multiple billions of dollars.
I don't see material upside or downside (for Boston Scientific shares) for the next 12 months.
This offer is superior. This offer promises a higher price, stock with better appreciation potential, commitments to do what it takes to avoid antitrust concerns, and a firm timeline.
We are operating in a large vacuum. It's exceedingly difficult to speculate.
This is a very simple integration. It should not be difficult.
You can't just sit back on your laurels. You have to constantly innovate.
I would venture that we are now outside of gentlemanly territory,